Kelley Boucher - 02 Sep 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief People Officer
Signature
/s/ David Watson, attorney-in-fact for Kelley Boucher
Issuer symbol
APLS
Transactions as of
02 Sep 2025
Net transactions value
$0
Form type
4
Filing time
03 Sep 2025, 11:55:16 UTC
Previous filing
11 Jun 2025
Next filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boucher Kelley Chief People Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Kelley Boucher 03 Sep 2025 0002070437

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +30,476 +45% $0.000000 97,658 02 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $0 +45,766 $0.000000 45,766 02 Sep 2025 Common Stock 45,766 $28.17 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock unit was granted on September 2, 2025. The restricted stock unit will vest 25% annually over four years from grant date, subject to her continued service as an officer, or upon later termination of her service.
F2 This represents a stock option award granted September 2, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.